BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 20654019)

  • 1. [Tolerability of 6-mercaptopurine in children with acute lymphoblastic leukemia].
    Ma XL; Wang B; Guo HY; Zhang YH; Zhu GH; Duan YL; Yang J; Zhang DW; Jin L; Zhang R; Zhang L; Xie J; Wu MY
    Zhonghua Er Ke Za Zhi; 2010 Apr; 48(4):289-92. PubMed ID: 20654019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiopurine methyltransferase polymorphisms and mercaptopurine tolerance in Turkish children with acute lymphoblastic leukemia.
    Albayrak M; Konyssova U; Kaya Z; Gursel T; Guntekin S; Percin EF; Kocak U
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1155-9. PubMed ID: 21400026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Thiopurine S-methyltransferase gene sequence analysis of ALL children severely intolerant to 6-mercaptopurine].
    Ma XL; Li WJ; Zheng J; Wang B; Jin M; Zhang DW; Li ZG; Zhang YX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):876-9. PubMed ID: 22931646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NUDT15 and TPMT genetic polymorphisms are related to 6-mercaptopurine intolerance in children treated for acute lymphoblastic leukemia at the Children's Cancer Center of Lebanon.
    Zgheib NK; Akika R; Mahfouz R; Aridi CA; Ghanem KM; Saab R; Abboud MR; Tarek N; El Solh H; Muwakkit SA
    Pediatr Blood Cancer; 2017 Jan; 64(1):146-150. PubMed ID: 27577869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of NUDT15 on incidence of neutropenia in children with acute lymphoblastic leukemia.
    Buaboonnam J; Sripatanatadasakul P; Treesucon A; Glomglao W; Siraprapapat P; Narkbunnam N; Vathana N; Takpradit C; Phuakpet K; Pongtanakul B; Tongsai S; Sinlapamongkolkul P; Sanpakit K
    Pediatr Int; 2019 Aug; 61(8):754-758. PubMed ID: 31166660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia.
    Schmiegelow K; Björk O; Glomstein A; Gustafsson G; Keiding N; Kristinsson J; Mäkipernaa A; Rosthøj S; Szumlanski C; Sørensen TM; Weinshilboum R
    J Clin Oncol; 2003 Apr; 21(7):1332-9. PubMed ID: 12663723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allopurinol Use During Maintenance Therapy for Acute Lymphoblastic Leukemia Avoids Mercaptopurine-related Hepatotoxicity.
    Giamanco NM; Cunningham BS; Klein LS; Parekh DS; Warwick AB; Lieuw K
    J Pediatr Hematol Oncol; 2016 Mar; 38(2):147-51. PubMed ID: 26808368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
    Schmiegelow K; Bretton-Meyer U
    Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic Exposure to Thiopurines and Risk of Relapse in Children With Acute Lymphoblastic Leukemia: A Children's Oncology Group Study.
    Bhatia S; Landier W; Hageman L; Chen Y; Kim H; Sun CL; Kornegay N; Evans WE; Angiolillo AL; Bostrom B; Casillas J; Lew G; Maloney KW; Mascarenhas L; Ritchey AK; Termuhlen AM; Carroll WL; Wong FL; Relling MV
    JAMA Oncol; 2015 Jun; 1(3):287-95. PubMed ID: 26181173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942).
    Jacobs SS; Stork LC; Bostrom BC; Hutchinson R; Holcenberg J; Reaman GH; Erdmann G; Franklin J; Neglia JP; Steinberg SM; Balis FM; Adamson PC; ;
    Pediatr Blood Cancer; 2007 Sep; 49(3):250-5. PubMed ID: 16856155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiopurine S-methyltransferase (TPMT) polymorphisms in children with acute lymphoblastic leukemia, and the need for reduction or cessation of 6-mercaptopurine doses during maintenance therapy: the Polish multicenter analysis.
    Peregud-Pogorzelski J; Tetera-Rudnicka E; Kurzawski M; Brodkiewicz A; Adrianowska N; Mlynarski W; Januszkiewicz D; Drozdzik M
    Pediatr Blood Cancer; 2011 Oct; 57(4):578-82. PubMed ID: 21319286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Importance of genotyping of thiopurine S-methyltransferase in children with acute lymphoblastic leukaemia during maintenance therapy].
    Dokmanović L; Janić D; Krstovski N; Zukić B; Tosić N; Pavlović S
    Srp Arh Celok Lek; 2008; 136(11-12):609-16. PubMed ID: 19177822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study.
    Mahoney DH; Shuster JJ; Nitschke R; Lauer S; Steuber CP; Camitta B
    J Clin Oncol; 2000 Mar; 18(6):1285-94. PubMed ID: 10715299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Correlations between 6-mercaptopurine treatment-related adverse reactions in children with acute lymphoblastic leukemia and polymorphisms of thiopurine methyltransferase gene].
    Xie C; Yue LJ; Ding H; Ren YF; Yang CL; Zheng MM
    Zhongguo Dang Dai Er Ke Za Zhi; 2014 May; 16(5):499-503. PubMed ID: 24857000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia.
    Adam de Beaumais T; Dervieux T; Fakhoury M; Medard Y; Azougagh S; Zhang D; Yakouben K; Jacqz-Aigrain E
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):653-8. PubMed ID: 20033410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group--protocol ALL-99.
    Brandalise SR; Pinheiro VR; Aguiar SS; Matsuda EI; Otubo R; Yunes JA; Pereira WV; Carvalho EG; Cristofani LM; Souza MS; Lee ML; Dobbin JA; Pombo-de-Oliveira MS; Lopes LF; Melnikoff KN; Brunetto AL; Tone LG; Scrideli CA; Morais VL; Viana MB
    J Clin Oncol; 2010 Apr; 28(11):1911-8. PubMed ID: 20212252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The activity of the inosine triphosphate pyrophosphatase affects toxicity of 6-mercaptopurine during maintenance therapy for acute lymphoblastic leukemia in Japanese children.
    Tanaka Y; Manabe A; Nakadate H; Kondoh K; Nakamura K; Koh K; Utano T; Kikuchi A; Komiyama T
    Leuk Res; 2012 May; 36(5):560-4. PubMed ID: 22200619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Relationship between single nucleotide polymorphisms in thiopurine methyltransferase gene and tolerance to thiopurines in acute leukemia].
    Ma XL; Zhu P; Wu MY; Li ZG; Hu YM
    Zhonghua Er Ke Za Zhi; 2003 Dec; 41(12):929-33. PubMed ID: 14723818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations.
    Lancaster DL; Lennard L; Rowland K; Vora AJ; Lilleyman JS
    Br J Haematol; 1998 Jul; 102(2):439-43. PubMed ID: 9695957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of intravenous 6-mercaptopurine during continuation treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma: final results of a randomized phase III trial (58881) of the EORTC CLG.
    van der Werff Ten Bosch J; Suciu S; Thyss A; Bertrand Y; Norton L; Mazingue F; Uyttebroeck A; Lutz P; Robert A; Boutard P; Ferster A; Plouvier E; Maes P; Munzer M; Plantaz D; Dresse MF; Philippet P; Sirvent N; Waterkeyn C; Vilmer E; Philippe N; Otten J
    Leukemia; 2005 May; 19(5):721-6. PubMed ID: 15744348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.